First Name
Last Name
Email Address


8:15 – 9:15 Dr. Anderson Assessment of the cancer patient across the spectrum – Part-1

1. Standard tumor markers were touched on but not discussed in detail:

2. Non-specific markers like AlkPhos, CRP, LDH etc. are best used:

3. Two nutrient markers that can rise with cancer advancement mentioned were:

9:15 – 10:15 Dr. Tims Assessment of the cancer patient across the spectrum – Part-2

1. The idea of a “Liquid Biopsy” was mentioned:

2. Circulating tumor cells are 100% sensitive and specific:

3. As discussed in this session, CTC’s are:

11:00 – 12:00 Dr. Price Nutrigenomic Analysis: Assessing Genetic Analysis in Complementary Cancer Care and Culinary Nutrition/Assessing Epigenetic Guidance in Culinary Nutrition and Supplementation

1. “Nutrigenomics” refers to:

2. Knowing a patient’s SNP profile can help with:

3. Nutrigenomics can be used to:

2:30 – 3:30 Dr. Anderson Metabolic complications in the Patient with Cancer

1. Lymphedema is a mentioned disease complication of cancer:

2. Marrow Suppression is a mentioned disease complication of cancer:

3. RDW can be used to assess:

4:45 – 5:15 Dr. Anderson Early assessment of cancer: What to watch for

1. “Red Flags” mentioned include:

2. The concept of “documenting and monitoring suspicions” was:

3. If you enter “Rule Out” in your chart ‘Plan’ you:


8:30 – 9:30 Dr. Abrams Nutrition and Cancer Guidelines: Updated but are they Upgraded?

1. This presentation discussed the WCRF/AICR Guidelines:

2. Patient weight is not a part of this discussion:

3. This session promoted the idea of “only one diet for cancer”:

11:15 – 12:15 Dr. Anderson Diet through the Four Phases of Cancer

1. The four phases include:

2. This presentation focused on:

12:15 – 12:45 Dr. Price Implementing Food as Medicine – from Theory to Plate

1. The use of herbs – spices in diet was mentioned in this session:

2. This presentation promoted a high meat intake for cancer:

3. A potentially medicinal spice mentioned was turmeric:

2:30 – 3:15 Dr. Espinosa Prostate Cancer Part-1: Top therapeutics and recent updates

1. This session mentioned ____ as possible use in low risk PrCA:

2. In this session medicinal mushrooms for low risk PrCA were:

3. The overall idea presented was Low risk PrCA and Advanced PrCA are treated identically

4:30 – 5:30 Dr. Tims / DrH Breast cancer - Top therapeutics and recent updates

1. This session discussed “restoring metabolic flexibility”

2. This session discussed therapies with:

3. Lymph drainage and colon hydrotherapy were discussed:


8:30 – 9:00 Dr. Espinosa Prostate Cancer Part-2: The “other” Prostate Cancer.

1. This session asserted:

2. Managing ADT side effects was discussed:

3. Diet in advanced PrCA was said to best include:

9:00 – 9:30 Dr. Anderson Prostate Cancer Part-3: Considerations in metastatic Prostate Cancer

1. This session made the point that advanced PrCA:

2. A case for infections as comorbid and aggravating factors was made:

3. In addition to the above, a case was made for assessing _____ in advanced PrCA:

11:15 – 12:15 Dr. Abrams Cannabis in Cancer Care

1. The only legitimate medical cannabinoid is d-9 THC

2. The following are researched medical cannabinoids:

3. Medical cannabinoids are:

2:15 – 3:15 Dr. Abrams Integrating Traditional Chinese Medicine into Holistic Cancer Care

1. Chinese Medicine is limited to acupuncture:

2. The following may be part of a Chinese Medicine intervention:

3. Regarding the use of herbs from a Chinese medicine perspective:

3:15 – 4:15 Dr. Anderson Cancer Therapeutics a discussion of “Starving Cancer” and “Repurposed Drugs” in Oncology.

1. Repurposed drugs are:

2. An example of a repurposed drug for oncology is:

3. The point was made that repurposed drugs have a place but not at the exclusion of all the foundational therapies: